Last reviewed · How we verify
MUC-2-KLH vaccine
At a glance
| Generic name | MUC-2-KLH vaccine |
|---|---|
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer (PHASE1)
- Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer (PHASE1)
- Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer (PHASE1)
- Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MUC-2-KLH vaccine CI brief — competitive landscape report
- MUC-2-KLH vaccine updates RSS · CI watch RSS
- Memorial Sloan Kettering Cancer Center portfolio CI